EGFR and non-small cell lung carcinoma: A study evaluating post-progression outcomes with first-line osimertinib versus standard-of-care EGFR-TKIs, provided further confidence in the interim OS data of the FLAURA study and advocated use of osimertinib as first-line therapy for EGFR mutant (EGFRm) advanced NSCLC [45].